| Measurement points | Method(s) of measurement | |
---|---|---|---|
 | Immediately after index office visit | 12 week follow-up |  |
Sub-study 1: patients with clinically significant depressive symptoms (baseline PHQ-9 ≥ 5) |  |  |  |
   Process of care |  |  |  |
     Key outcome - components of initial depression care (CIDC): antidepressant prescription and/or mental health referral among participants with baseline PHQ-9 ≥ 10* | X |  | PQ, PCPQ, MRR |
     Others |  |  | |
       Antidepressant prescription and/or mental health referral among all sub-study participants* | X |  | |
       Follow-up with PCP at an appropriate interval†| X |  | |
       Inquiry regarding self-harm/suicidal thoughts | X |  | |
   Patient function |  |  |  |
     PHQ-8‡ score | X | X | PQ |
     SF-12 Mental Component Summary score |  | X | |
     SF-12 Physical Component Summary score |  | X | |
   Patient engagement in depression care |  |  |  |
     Readiness |  |  | PQ |
       To discuss depression (in general) with PCP | X |  | |
       To discuss depression treatment with PCP | X |  | |
     Self-efficacy |  |  | |
       For recognizing depression | X | X | |
       For discussing depression with PCP | X | X |  |
     Provider-patient interaction |  |  | PQ, PCPQ, MRR |
       Discussion of depression | X |  | |
       Patient request for depression treatment | X |  | |
   Patient perceived depression stigma | X | X | PQ |
Sub-study 2: patients without clinically significant depressive symptoms (baseline PHQ-9 < 5) |  |  |  |
   Process of care |  |  |  |
     Antidepressant prescription (over-treatment) | X |  | PQ, PCPQ, MRR |
     Distraction effects |  |  | |
       Index office visit length | X |  | |
       Patient request for depression treatment | X |  | |
       Physician visit effort | X |  |  |
   Patient function |  |  |  |
     SF-12 Physical Component Summary score (potential toxicity, i.e. reduced function) |  | X | PQ |
     Patient perceived depression stigma (potential reduction) | X | X | PQ |